| |
Newsroom /
Environment
/
Environment
/
Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
OA Pain Therapeutics Market is forecast to Show Slow Growth until 2017
Hyderabad,
AP,
India
(prbd.net)
28/04/2011
GlobalData estimates that the global osteoarthritis (OA) pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to low levels of treatment-seeking behavior, disease awareness and the usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.
Abbott Laboratories, Adolor Corporation, Cephalon, Inc., Endo Pharmaceuticals, Elite Pharmaceuticals, Glenmark Pharmaceuticals, Grunenthal GMBH, Johnson & Johnson Pharmaceuticals Ltd., Pfizer, Inc., SantaSolve AS, and Sanofi-aventis are going to be the key players in the OA pain market. GlobalData has profiles of all these companies as they hold important pipeline drugs in late stage development for OA Pain treatment.
The existing market landscape remains competitive, because the treatment of OA Pain relies on established, older therapies like non-steroidal anti-inflammatory drugs (NSAIDS), opioids, and Cyclooxygenase-II (COX-II) inhibitors. The market scenario is expected to change after the launch of new disease modifying therapies such as TRPV1, 3 antagonists, aggrecanase inhibitors, GABA B receptor modulators, inducible nitric oxide synthase (iNOS) inhibitor, platelet secreted growth factors, and Anti NGF mAB.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Osteoarthritis-OA-Pain-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
GlobalData analysis shows that the OA Pain therapeutics development pipeline is strong, with 49 molecules in various phases of clinical development, including 29 first-in-class molecules. These first-inclass molecules are mostly in the early stages of clinical development, so their impact on the market will be at a later stage. As a result, the pipeline for the OA Pain therapeutics market is expected to have a bigger impact on the market in the later stages of the forecast period, thus providing a wide scope of growth in the future.
GlobalData’s research indicates that the OA Pain therapeutics pipeline is strong, with a number of molecules in various phases of clinical development. The first-in-class molecules seem to have distinct advantages over the current products in terms of better disease management. Although the unmet need of the OA Pain therapeutics market is low and the treatment relies on older therapies and drugs, the market needs novel therapies offering better results in terms of safety and efficacy.
GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global osteoarthritis pain market. The report identifies the key trends shaping and driving the global osteoarthritis pain market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global Osteoarthritis pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoarthritis-OA-Pain-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|